

Investor Factsheet Q1 2022

Captor Therapeutics is a biopharmaceutical company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

Captor Therapeutics is a Polish-Swiss company.

Our competitive advantages



Develop and commercialize drug candidates



Drug discovery platform



Partnerships

What is Targeted Protein Degradation?

Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called “undruggable proteome”.

Our current projects

	Indications	Modality	Discovery	Preclinical*	IND Filing	FIH**
CT-01	Hepatocellular carcinoma GSPT1, SALL4, undisclosed target	MG				
CT-02	Autoimmunity Liquid tumors	MG				
CT-03	Liquid & solid tumours MCL-1	BID				
CT-04	Colorectal cancer	BID				
CT-05	Autoimmunity Solid tumours & other	BID				
	Partnered Program					
	Gastrointestinal diseases, e.g. IBD					Partnership with Sosei Heptares

*Preclinical stage include IND-enabling studies; **First in Human; at least 2 projects expected to enter Phase 1 by 2023; **BID** - Bi-functional Degradar; **MG** - Molecular Glue

Key events Q1 2022

- In project CT-01 with targets GSPT1 & SALL4 and main indication in hepatocellular carcinoma, we have achieved:**
 - Anticancer activity in different HCC models in vitro
 - Good efficacy achieved after oral administration
 - Strong tumor inhibition and tumor regression shown in mice bearing HCC tumors demonstrated with two candidate molecules in vivo
- In project CT-03 with target MCL-1 and main indication in blood cancers, we have achieved:**
 - Anticancer activity in vitro in both liquid and solid tumors
 - Potent and sustained MCL-1 degradation in vivo after single dose
 - Cancer cells' killing in vivo
- Both CT-01 and CT-03 are expected to begin clinical trials in 2023.**
- Organization of two events for shareholders in May this year: Investors' Day for financial analysts and R&D Day for experts from the biopharmaceutical industry.**
- We take active participation in the most prestigious conferences of your sector, e.g.:**
 - The 4th Annual Targeted Protein Degradation (TPD) Summit
 - Bio Digital 2021
 - 2nd Annual Targeted Protein Degradation Europe Summit
 - LSX World Congress 2022
- We are gradually adding top-notch equipment to our laboratories e.g Orbitrap Exploris 480 mass spectrometer**

Employees (data as of 31/03/2022)


Number of employees	101
Number of research workers	90
Percentage of scientists with PhD	45%



20%


research workers increase in Q1 2021

Consolidated statement of financial position (PLN, thousand)



Available funding secured

(PLN M; as of 31.03.2022)




PLN 111 M cash

PLN 94 M agreements with NCBR

Total PLN 205 M

Shareholding Structure – 31.03.2022



Share capital	Shareholder
22.18%	Michał Walczak
14.29%	Paweł Holstinghausen Holsten
8.26%	Sylvain Cottens
7.34%	Funds Managed by Nationale-Nederlanden - Powszechna Towarzystwo Emerytalne S.A.
47.93%	Others

Stock exchange info

Company listed on Warsaw Stock Exchange (GPW): CAPTORTX



Market capitalization (May 2022)

PLN 638 M

IPO value (April 2021)

~ PLN 150 M

Reduction of the retail tranche in IPO

~ 92%

Upcoming financial events



22 September 2022
Release H1 2022



24 November 2022
Release Q3 2022

This document has been prepared by Captor Therapeutics S.A. (the "Company") for information purposes only (the "Document"). The Document does not contain all the information that may be required to evaluate the Company (or its shares). The Document does not contain a complete and exhaustive analysis or description of situation of the Company. Any person who intends to make an investment decision relating to the Company should take into account mainly official announcements of the Company (i.e. current/periodic reports) published in accordance with the law. The document also contains certain forward-looking statements. Because of their nature, the Company makes no representation (promise, guarantee) that any of such statements will be realized or prove correct. The Company's actual future results and operations may differ materially from the forward-looking statements contained in the Document. The Document was prepared as of a specific date and the information contained therein may become outdated.

The Document does not constitute or form part of, and should not be construed as, any offer to sell or issue, or any solicitation of any offer to purchase, subscribe for or acquire, any securities of the Company or any solicitation of any investment activity in any jurisdiction in which such offer, solicitation, invitation or sale would be unlawful. No part of this Document, nor the fact of its distribution, should form the basis of, or be relied upon in connection with, any contract, commitment or investment decision. The Document is not intended for publication, release or distribution in, or should not be distributed or transmitted to, any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.